

Freedom of Information Request: Our Reference CTMUHB_188_21

You asked:

I have a Freedom of Information request and I would greatly appreciate if you could answer the below three questions:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Tofacitinib
- Ustekinumab
- Vedolizumab

Our response:

In response to questions 1 and 3 of your recent enquiry as outlined above please find below a table populated with the data we hold for the period of 1st January, 2021 to 31st March, 2021. Unfortunately, due to the recent implementation of a new electronic dispensing system in Pharmacy we are unable to provide any further information at this moment in time.

Dermatology	Total
Adalimumab - Humira	**
Adalimumab Biosimilar	0
Apremilast	29
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	**
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	**
Ixekizumab	0
Risankizumab	0
Secukinumab	0
Tildrakizumab	0
Ustekinumab	0
Gastroenterology	
Adalimumab - Humira	10
Adalimumab Biosimilar	82
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	174
Tofacitinib	**
Ustekinumab	30
Vedolizumab	74

Please note the following:

- (a) with reference to the numbers stated for dermatology appearing to be low; this is because patients' that require biologic treatments are referred into the dermatology services of a neighbouring Health Board.
- (b) Where the numbers are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In response to question 2:

This level of information is not captured on our Pharmacy system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Dermatology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.